Akums Drugs and Pharmaceuticals Gears Up for Q3 Reveal on 13th February. Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 12 Feb 2026 • 3:39 pm
Posted by:
Akums Drugs and Pharmaceuticals' Q3 results FY26 are scheduled to be announced on 13th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Akums Drugs and Pharmaceuticals Q3 Results 2026 Preview
- Akums Drugs and Pharmaceuticals' revenue is expected to be in the range of ₹75.04 crore, a 58.89% YoY increase.
- Profit After Tax, or PAT, is projected to fall 2.19% YoY.
- Net profit is ₹5.27 crore, a fall of 0.04% YoY
- EBITDA to fall 9.32%
Akums Drugs and Pharmaceuticals Share Performance
- Over the past six months, Akums Drugs and Pharmaceuticals' share price has risen by 3.27% to ₹465.30.
- Moreover, over the past year, the stock has decreased by 15.39%.
- Despite this weak short-term performance, Akums Drugs and Pharmaceuticals' stock has delivered a financially sound 42.07% return over the past 5 years.
- As of 12th February 2026, the stock traded at ₹465.30 per share.
About Akums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals was incorporated in 2004 and is an Indian pharmaceutical contract development and manufacturing organisation that operates with both domestic and multinational pharmaceutical companies. Its revenue was about ₹1,538.75 crore. The total assets at the end of FY2025 were about ₹2,095.43 crore.
Key Factors to Watch for Akums Drugs and Pharmaceuticals Q3 Results FY26
- Revenue Growth & Order Book
To check the company's revenue growth, especially from contract manufacturing and export orders. A strong order book give positive signal for future growth.
- Operating Margins & Cost Control
To track the impact of raw materials, packaging, and logistics costs on margins, helping improve overall profitability through effective cost control.
- Client Addition & Retention
To effectively check whether the company has added new pharma clients and retained existing ones. Stable and increasing order reflects in business sustainability.
- Capacity Utilisation & Approvals
Monitor the capacity of manufacturing plants and the progress of capacity expansion projects to determine future revenue potential.
Final Thoughts
Akums Drugs and Pharmaceuticals will announce its Q3 FY26 results on 13th February 2026. Analysts expect 2.19% revenue growth, a 0.04% fall in PAT, and a 9.32% rise in EBITDA. Akums Drugs and Pharmaceuticals focuses on revenue growth from order execution, margin improvement, the strength of the order book, and management.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
GOCL Corporation Q3 Results FY26 Preview
Godrej Industries Q3 Results FY26 Preview
Godawari Power and Ispat Q3 Results FY26 Preview
Himatsingka Seide Q3 Results FY26 Preview
Igarashi Motors India FY26 Preview
Recent Articles
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
30 October 2026
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
30 October 2026
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
30 October 2026
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
30 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gold Price Today, 30 October 2026: MCX Gold Falls 1.25% to Rs 1,40,808 Per 10 Grams and Spot Gold Slips Below $4,000, a 3.5-Month Low, as December Fed Hike Bets Build Ahead of Dhanteras
Anthropic IPO Valuation: Aswath Damodaran Values the Claude Maker at $1.475 Trillion, Just Below the Reported $1.5 to $2 Trillion IPO Range, With Scenarios From Negative $373 Billion to $4.04 Trillion
Equitas Small Finance Bank Share Price Crashes 10% to Rs 51.25 on 30 October 2026, Down 21% in Two Days After CEO PN Vasudevan Resigns Despite Record Equitas Q2 Results: What Is Going On?
Greaves Cotton Share Price Jumps 10% Despite 81% Fall in Q2 Profit: What Is Driving the Rally?
Asian Paints Share Price After Q2 Results: Profit Up 7%, but Price Hikes Are Yet to Brighten Margins
Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times